Latest News & Features
Americas
A Delaware jury found AstraZeneca liable for induced infringement of a cancer treatment in May | Pharma company levelled allegations of "unclean hands" and "patent misuse" at Pfizer unit. 8 August 2024
Careers
The firm adds three partners to its New York office | Expansion brings a combined 60 years of experience | Hires experienced in high-stakes patent disputes involving biologics, small-molecule drugs, and medical devices. 8 August 2024
Americas
District court partially grants Ultrahuman Healthcare's motion to stay patent litigation with Oura Health, pending an ITC investigation | Court's order pauses several patent claims | Decision allows Oura's copyright allegations to proceed independently. 6 August 2024
Americas
Big pharma subsidiary and Japanese collaborator allege infringement of blockbuster drug product | $1.2 billion treatment developed by University of California. 6 August 2024
Americas
Pharma company argues that affirming lower court’s decision would shrink Orange Book “dramatically” | District court found Teva’s patents do not claim the drug product for which they are listed. 1 August 2024
Americas
Being a lawyer with ADHD is far from easy due to widespread misconceptions about the condition but there are ways to offer support, says Lisa Mueller of Casimir Jones. 1 August 2024
Americas
Senior partner in IP department will become co-managing partner | Foley Hoag elected three other members of five-strong executive committee this year 1 August 2024
Americas
Biopharmaceutical company insisted its cancer treatment should be considered a biologic | Panel finds “unfairly reductive” arguments “just don’t work” | FDA correct to reject Ipsen based on faulty scientific expertise. 30 July 2024
Americas
Massachusetts biotech giants clash as Genzyme alleges Sarepta's Elevidys infringes on key gene therapy patents | Despite the dispute, Elevidys $200M in sales and recent FDA approvals show success. 30 July 2024
Americas
Hongene Biotech challenged ChemGenes’ patent after litigation withdrawn | Judges said all challenged claims were unpatentable. 25 July 2024